












13<sup>th</sup> Annual

# Immunogenicity & Bioassay Summit

OCTOBER 18-22, 2021

THE WATERGATE HOTEL | WASHINGTON, DC & ONLINE [EDT]

## CONFERENCE AT-A-GLANCE

Monday   October 18	Tuesday   October 19	Wednesday   October 20	Thursday   October 21	Friday   October 22	
<p><b>Monday AM</b> SC1: Mechanism of Action and Risk-Based Approach for Developing Neutralizing Ab Assays</p>	<p> Symposium 1: Immunology for Biotherapeutics</p>	<p> <b>C1A:</b> Immunogenicity Assessment &amp; Clinical Relevance</p>	<p> <b>C1A:</b> Immunogenicity Assessment &amp; Clinical Relevance</p>	<p> <b>C1B:</b> Immunogenicity Prediction &amp; Control</p>	
<p><b>Monday PM</b> SC2: Overcoming Drug and Target Interference in ADA Assays</p>		<p> <b>TS1: An Introduction to Bioassay Design, Analysis, Validation, and Monitoring</b></p>	<p><b>Training SEMINARS</b> by Cambridge Healthtech Institute <b>TS1: An Introduction to Bioassay Design, Analysis, Validation, and Monitoring</b></p>		<p><b>Training SEMINARS</b> by Cambridge Healthtech Institute <b>TS1: An Introduction to Bioassay Design, Analysis, Validation, and Monitoring</b></p>
<p><b>Monday PM</b> SC3: Validation of ADA Assays and Cut Point Calculations</p>	<p> Presented In-person &amp; Online</p>	<p> Presented Online</p>	<p> <b>C1B:</b> Immunogenicity Prediction &amp; Control</p>	<p> <b>C2B:</b> Optimizing Bioassays for Biologics</p>	
<p><b>Monday PM</b> SC4: Recent Advances with Gene and Cell Therapy</p>			<p> <b>C2B:</b> Optimizing Bioassays for Biologics</p>		<p> <b>C2B:</b> Optimizing Bioassays for Biologics</p>
<p><b>Monday PM</b> SC5: Advice on Putting Together an Integrated Summary of Immunogenicity</p>			<p><b>Thursday PM</b> SC6: Advanced Strategic Bioassay Design</p>		

#ImmunoBio21 | ImmunogenicitySummit.com

Connect with Us



#ImmunoBio21